Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Drug Recall: Single lot of Phenobarbital recalled

    by
    • Optum Workers' Comp
    | Apr 21, 2017
    Tag Icon
    Medication Recall, FDA
    The U.S. Food and Drug Administration (FDA) announced C.O. Truxton, Inc. voluntarily recalled one lot of Phenobarbital 15 mg tablets after the manufacturer received a complaint that a bottle was mislabeled. According to the manufacturer, a bottle labeled as 15 mg contained 30 mg tablets.


  • You Are Being Watched

    by
    • Lavonya Chapman Esq RN CMSP
    | Apr 18, 2017
    Tag Icon
    Medicare Advantage Plans, NGHP, medicareinsights blog, CMS, Medicare Secondary Payer
    All non-group health plans (NGHP) including all property & casualty insurers who insure auto no-fault (Med Pay/PIP) claims, workers’ compensation claims, premises Med Pay claims, get your assumption and/or termination of ongoing responsibility for medicals (ORM) reporting in order, a firm called MSP Recovery is coming after you.


  • A Tale of Two Formulary Bills and Controlling Opioids in the Pelican State

    by
    • Optum Workers' Comp
    | Apr 13, 2017
    Tag Icon
    Formularies, Opioids
    The 2017 General Session of the Louisiana legislature got off to a running start on Monday, April 10th. Legislators in the Pelican State will be considering two competing workers’ compensation drug formulary bills.


  • New York Formulary in the Works

    by
    • Optum Workers' Comp
    | Apr 11, 2017
    Tag Icon
    Formularies
    The New York legislature passed a late night budget agreement on Sunday, April 9, 2017, following several days of off-again on-again negotiations. Included in the adopted budget language was a provision directing the New York Workers’ Compensation Board to establish a comprehensive prescription drug formulary on or before December 31, 2017.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.